Itaconix reports record H1 sales as it hits growth targets across all markets

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw takes Proactive's Stephen Gunnion through the company’s latest financial results and operational progress as it continues its push towards profitability and scale. Shaw said, “We’re going to be a large specialty ingredient company. 20 million, 40 million, 100 million. Those are our ambitions,” highlighting confidence in the company’s growth prospects through scale inhibitors and odour neutralisers used in high-performing detergents. He outlined progress against four key goals for 2025, including rebuilding the North American cleaning customer base, expanding in Europe, increasing adoption of odour neutralisers, and launching its biomaterials platform. Shaw confirmed the company has already achieved these, with its SPARX programme set to deliver 10 new products to market by year-end. He also referenced recent momentum in Europe, new commercial traction through a partnership with Croda, and early demand via e-commerce for its BIOAsterix offering. On capacity, Shaw said the company is positioned to meet forecast demand through 2026 and is already preparing for 2027, noting that longer-term plans may include new facilities to support larger customer volumes. Shaw expressed confidence in ending 2025 strongly and expects continued growth into 2026. For more updates from Itaconix and other innovative companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #Itaconix #SpecialtyIngredients #OdourNeutralisers #PlantBasedChemicals #SustainableIngredients #DetergentInnovation #JohnShaw #CleanTech #Croda #InvestorUpdate #SPARXProgramme #BIOAsterix #ProfitabilityPath #GreenChemistry #ProactiveInvestors